Pregnancy Outcomes in Patients Treated with TNF Inhibitors

A study found the continuation of tumor necrosis factor inhibitor (TNFi) treatment in patients with chronic rheumatic inflammatory diseases after pregnancy diagnosis was not associated with worse outcomes than those who discontinued treatment with TNFi’s.

Source: The Rheumatologist - December 18, 2023 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: ACR Convergence Biologics/DMARDs Conditions Drug Updates Meeting Reports ACR Convergence 2023 pregnancy pregnant women tumor necrosis factor inhibitor (TNFi) Source Type: research